Financial
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Gleamer
HQ France · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Not assessed
Customer rating
No reviews yet
Financial health
Band: Not assessedPrivately held
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Mar 2026: US imaging group RadNet agreed to acquire Gleamer for up to €230m in cash, to be integrated into its AI subsidiary DeepHealth.
Cyber & information governance
No data breaches or cyber incidents involving Gleamer found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
No recalls, safety notices or other regulatory actions involving Gleamer found in HSH's search of the last 24 months.
Contract performance
Jan 2026: Northern Ireland deployed Gleamer's BoneView fracture-detection AI for emergency departments through PACS supplier Sectra.
Competitors
No competitors linked yet.